Ftse Mib
34.235,55
-0,41%
DAX
18.519,74
-0,43%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
62.936,38
-2,95%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX BioPharmX Corporation (BPMX) BioPharmX Corporation (BPMX) Notizie

BPMX

BioPharmX (BPMX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX
DataOraFonteTitoloSimboloCompagnia
28/01/202022:30PR Newswire (US)BioPharmX And Timber Pharmaceuticals Announce Entry into Merger AgreementAMEX:BPMXBioPharmX Corporation
15/01/202016:06Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)AMEX:BPMXBioPharmX Corporation
10/12/201922:51Edgar (US Regulatory)Quarterly Report (10-q)AMEX:BPMXBioPharmX Corporation
10/12/201922:07Edgar (US Regulatory)Current Report Filing (8-k)AMEX:BPMXBioPharmX Corporation
10/12/201922:05PR Newswire (US)BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate UpdateAMEX:BPMXBioPharmX Corporation
20/09/201922:05PR Newswire (US)BioPharmX Receives Notice of Compliance Deadline Extension from NYSE AmericanAMEX:BPMXBioPharmX Corporation
09/09/201914:15PR Newswire (US)BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate UpdateAMEX:BPMXBioPharmX Corporation
18/07/201923:42Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:BPMXBioPharmX Corporation
18/07/201923:31Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:BPMXBioPharmX Corporation
16/07/201922:15PR Newswire (US)BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating OfficerAMEX:BPMXBioPharmX Corporation
25/06/201913:30PR Newswire (US)BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular RosaceaAMEX:BPMXBioPharmX Corporation
11/06/201922:10PR Newswire (US)BioPharmX Reports Fiscal First Quarter 2020 Financial ResultsAMEX:BPMXBioPharmX Corporation
22/05/201922:23Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:BPMXBioPharmX Corporation
22/05/201914:10PR Newswire (US)BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular RosaceaAMEX:BPMXBioPharmX Corporation
16/05/201923:06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)AMEX:BPMXBioPharmX Corporation
26/04/201913:30PR Newswire (US)BioPharmX Completes 1-for-25 Reverse Stock SplitAMEX:BPMXBioPharmX Corporation
15/04/201922:15PR Newswire (US)BioPharmX Announces Reverse Stock SplitAMEX:BPMXBioPharmX Corporation
21/03/201913:55PR Newswire (US)BioPharmX Announces $3.9 Million OfferingAMEX:BPMXBioPharmX Corporation
18/03/201911:45PR Newswire (US)BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare ConferenceAMEX:BPMXBioPharmX Corporation
14/03/201921:31Edgar (US Regulatory)Annual Report (10-k)AMEX:BPMXBioPharmX Corporation
14/03/201921:05PR Newswire (US)BioPharmX Reports Fourth Quarter and Full Year 2019 Financial ResultsAMEX:BPMXBioPharmX Corporation
04/03/201912:00PR Newswire (US)BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular RosaceaAMEX:BPMXBioPharmX Corporation
14/02/201912:50Edgar (US Regulatory)Notice of Effectiveness (effect)AMEX:BPMXBioPharmX Corporation
04/02/201913:00PR Newswire (US)BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd PlottAMEX:BPMXBioPharmX Corporation
31/01/201923:31Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)AMEX:BPMXBioPharmX Corporation
20/12/201822:30PR Newswire (US)BioPharmX Receives Notice of Noncompliance from NYSE AmericanAMEX:BPMXBioPharmX Corporation
07/12/201821:09Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)AMEX:BPMXBioPharmX Corporation
06/12/201822:10PR Newswire (US)BioPharmX Reports Third Quarter 2019 Financial ResultsAMEX:BPMXBioPharmX Corporation
16/11/201812:00PR Newswire (US)BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing ComplianceAMEX:BPMXBioPharmX Corporation
11/10/201822:30PR Newswire (US)BioPharmX Initiates Phase 2b Trial of BPX-04 for RosaceaAMEX:BPMXBioPharmX Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX

La tua Cronologia

BIT
WGIS26
Gismondi 1754
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network